Odanacatib

Odanacatib

{{Drugbox | IUPAC_name = (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl- 2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)- [1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide | image = Odanacatib.png | CAS_number = 603139-19-1 | CAS_supplemental = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = | DrugBank = | chemical_formula = | C=25 | H=27 | F=4 | N=3 | O=3 | S=1 | molecular_weight = 525.56 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }} Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.

It is being developed by Merck & Co. As of May 2008, Merck is conducting phase III clinical trials.

References

Search another word or see Odanacatibon Dictionary | Thesaurus |Spanish
Copyright © 2014 Dictionary.com, LLC. All rights reserved.
  • Please Login or Sign Up to use the Recent Searches feature
FAVORITES
RECENT

;